BioPharmSignal logoBioPharmSignal

Biotech News

Tango Therapeutics Appoints Sung Lee to Board of Directors

Tango Therapeutics (TNGX)Tango TherapeuticsCompany update

BOSTON, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today announced the appointment of Mr. Sung Lee to the Board of Directors. Mr.

Related news

TNGXTango Therapeutics2026-06-22 20:05 EST

Tango Therapeutics Appoints Robert Azelby to Board of Directors

TNGXTango Therapeutics2026-08-11 11:00 EST

Tango Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Highlights

KYMRKymera2026-06-24 20:01 EST

Kymera Therapeutics Appoints Felix J. Baker, Ph.D., as Chairman of the Board of Directors

FATEFate Therapeutics2026-06-15 12:30 EST

Fate Therapeutics Appoints Laura Hamill to Board of Directors

KYMRKymera2026-07-27 20:01 EST

Kymera Therapeutics Appoints Terence Rooney, MD, as Chief Medical Officer

NRIXNurix Therapeutics2026-08-20 11:00 EST

Nurix Therapeutics Announces Appointment of Wes Burwell as Chief Human Resources Officer

FATEFate Therapeutics2026-08-14 11:00 EST

Fate Therapeutics Initiates Potentially Registrational RECLAIM-LN Clinical Trial of FT819 for the Treatment of Lupus Nephritis

ELVNEnliven Therapeutics2026-08-05 20:05 EST

Enliven Therapeutics Reports Second Quarter Financial Results and Provides a Business Update

RLAYRelay Therapeutics2026-07-30 20:05 EST

Relay Therapeutics to Announce Second Quarter 2026 Financial Results and Corporate Highlights on August 6, 2026

CGEMCullinan Therapeutics, Inc.2026-07-28 11:00 EST

Cullinan Therapeutics Announces Positive End-of-Phase 1 Meeting with FDA for CLN-049 and Advances Program to a Potentially Registrational Phase 2 Study in AML

View all latest news

Tango Therapeutics

Synthetic Lethality Oncology Company Tango Therapeutics discovers targeted cancer medicines by identifying genetic dependencies created by tumor-suppressor loss. Vopimetostat Vopimetostat is a brain-penetrant, MTA-cooperative PRMT5 inhibitor for MTAP-deleted cancers. Development includes monotherapy and combinations intended to deepen...

Recent company news

TNGXTango Therapeutics2026-08-11 11:00 EST

Tango Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Highlights

TNGXTango Therapeutics2026-08-06 22:24 EST

Tango Therapeutics Announces Executive Chair Transition

TNGXTango Therapeutics2026-06-22 20:05 EST

Tango Therapeutics Appoints Robert Azelby to Board of Directors

TNGXTango Therapeutics2026-06-10 02:50 EST

Tango Therapeutics Announces Pricing of $600 Million Upsized Public Offering

TNGXTango Therapeutics2026-06-08 20:01 EST

Tango Therapeutics Announces Proposed $500 Million Public Offering

Stock data

Close
23.88 USD
Market cap
3.11B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States